OREON Life Science Introduces New HA Hybrid Fillerย
โi-NOVAโ at KIMES 2025... โTargeting the Global Aesthetics Marketโ
OREON Life Science participated in โKIMES 2025 (The 40th International Medical & Hospital Equipment Show),โ held from Thursday, March 20th to Sunday, March 23rd, across the entire COEX exhibition hall.
As a leading Korean medical aesthetics company for nearly 20 years, OREON Life Science specializes in manufacturing medical aesthetic devices such as lifting threads, hyaluronic acid (HA) fillers, and PLLA fillers. The company focuses on developing and producing medical devices for non-surgical and non-invasive treatments, currently distributing its products to over 70 countries worldwide.
At KIMES 2025, OREON Life Science showcased its flagship product line, the โi-Series.โ The โi-Seriesโ provides diverse skin improvement solutions, consisting of: โฒโi-LEAD,โ a monophasic HA filler; โฒโi-JUV,โ a skin booster containing PN (Polynucleotide); and โฒโi-NOVA,โ a new HA hybrid filler utilizing a combination of High-molecular and Low-molecular weight hyaluronic acid (H-HA with L-HA).
Among these, the โi-LEAD HA Fillerโ system is a premium cross-linked HA filler researched and manufactured in-house by i-LEAD, providing natural and sophisticated volumizing effects.
Key features highlighted include superior volume retention and enhanced durability achieved through the latest cross-linking technology. According to company officials, the product maximizes safety and minimizes side effects by using high-purity hyaluronic acid and a multi-stage purification process that reduces endotoxin levels to as low as 0.025 EU.
Furthermore, it was emphasized that the optimized formulation, containing 24mg of cross-linked HA, provides excellent viscoelasticity and lifting effects, delivering volume superior to existing fillers. The company stated, "It provides precise wrinkle improvement and effectively alleviates frown lines and brow wrinkles, maintaining natural expressions while creating a vibrant appearance."
OREON Life Science also shared its ambition to reshape the global skincare market through its new product, โi-NOVA.โ The company explained that this product is precisely engineered with an optimal combination of ingredientsโincluding high and low-molecular weight HAโto maximize skin hydration and regeneration. By blending regeneration-promoting raw materials such as amino acids, succinic acid, and glutathione, the product further strengthens natural healing power and elasticity improvement. Additionally, it is designed to deliver moisture deep into the skin and maintain it for a long period.
An OREON Life Science official stated, โThe i-Series is receiving consistent interest in the global market, and we plan to showcase our differentiated technological prowess through KIMES 2025.โ They added, โThe upcoming i-NOVA focuses on maximizing skin improvement through even more innovative ingredients and technology, and is expected to set a new standard in the global market.โ
๐ https://kr.aving.net/news/articleView.html?idxno=1798344ย
๐ https://www.medifonews.com/news/article.html?no=200039ย
๐ https://www.pharmnews.com/news/articleView.html?idxno=257974ย
๐ https://www.medworld.co.kr/news/articleView.html?idxno=243444ย
OREON Life Science Introduces New HA Hybrid Fillerย
โi-NOVAโ at KIMES 2025... โTargeting the Global Aesthetics Marketโ
OREON Life Science participated in โKIMES 2025 (The 40th International Medical & Hospital Equipment Show),โ held from Thursday, March 20th to Sunday, March 23rd, across the entire COEX exhibition hall.
As a leading Korean medical aesthetics company for nearly 20 years, OREON Life Science specializes in manufacturing medical aesthetic devices such as lifting threads, hyaluronic acid (HA) fillers, and PLLA fillers. The company focuses on developing and producing medical devices for non-surgical and non-invasive treatments, currently distributing its products to over 70 countries worldwide.
At KIMES 2025, OREON Life Science showcased its flagship product line, the โi-Series.โ The โi-Seriesโ provides diverse skin improvement solutions, consisting of: โฒโi-LEAD,โ a monophasic HA filler; โฒโi-JUV,โ a skin booster containing PN (Polynucleotide); and โฒโi-NOVA,โ a new HA hybrid filler utilizing a combination of High-molecular and Low-molecular weight hyaluronic acid (H-HA with L-HA).
Among these, the โi-LEAD HA Fillerโ system is a premium cross-linked HA filler researched and manufactured in-house by i-LEAD, providing natural and sophisticated volumizing effects.
Key features highlighted include superior volume retention and enhanced durability achieved through the latest cross-linking technology. According to company officials, the product maximizes safety and minimizes side effects by using high-purity hyaluronic acid and a multi-stage purification process that reduces endotoxin levels to as low as 0.025 EU.
Furthermore, it was emphasized that the optimized formulation, containing 24mg of cross-linked HA, provides excellent viscoelasticity and lifting effects, delivering volume superior to existing fillers. The company stated, "It provides precise wrinkle improvement and effectively alleviates frown lines and brow wrinkles, maintaining natural expressions while creating a vibrant appearance."
OREON Life Science also shared its ambition to reshape the global skincare market through its new product, โi-NOVA.โ The company explained that this product is precisely engineered with an optimal combination of ingredientsโincluding high and low-molecular weight HAโto maximize skin hydration and regeneration. By blending regeneration-promoting raw materials such as amino acids, succinic acid, and glutathione, the product further strengthens natural healing power and elasticity improvement. Additionally, it is designed to deliver moisture deep into the skin and maintain it for a long period.
An OREON Life Science official stated, โThe i-Series is receiving consistent interest in the global market, and we plan to showcase our differentiated technological prowess through KIMES 2025.โ They added, โThe upcoming i-NOVA focuses on maximizing skin improvement through even more innovative ingredients and technology, and is expected to set a new standard in the global market.โ
๐ https://kr.aving.net/news/articleView.html?idxno=1798344ย
๐ https://www.medifonews.com/news/article.html?no=200039ย
๐ https://www.pharmnews.com/news/articleView.html?idxno=257974ย
๐ https://www.medworld.co.kr/news/articleView.html?idxno=243444ย